[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527428":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":42,"responsibleParty":79,"collaborators":26,"id":82,"slug":26,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":83,"sex":89,"minAge":90,"maxAge":26,"enrollmentInfo":91,"targetDuration":26,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":26,"overallStatus":62,"whyStopped":26,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"St. Antonius Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Micro-encapsulated tributyrin granules, 4 grams three times daily, for a maximum of 14 days",[13],"Dietary Supplement: Micro-encapsulated granules of tributyrin (intervention)",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Micro-encapsulated sunflower oil granules, 4 grams three times daily, for a maximum of 14 days",[19],"Dietary Supplement: Micro-encapsulated granules of sunflower oil (placebo)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Micro-encapsulated granules of tributyrin (intervention)","Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Micro-encapsulated granules of sunflower oil (placebo)","Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days",[15],[32],{"name":33,"affiliation":5,"role":34},"H. C. van Santvoort, dr. prof.","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":40,"email":41},"Hannah Pauw, MD","CONTACT","0883207051","+31","ha.pauw@antoniusziekenhuis.nl",[43,61],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Reinier de Graaf Gasthuis","NOT_YET_RECRUITING","Delft","South Holland","2625AD","Netherlands",{"type":51,"coordinates":52},"Point",[53,54],4.35556,52.00667,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":59,"phoneExt":40,"email":60},"Rutger Quispel, dr. MD.","0152603089","r.quispel@rdgg.nl",{"facility":5,"status":62,"city":63,"state":64,"zip":65,"country":49,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"RECRUITING","Nieuwegein","Utrecht","3435CM",{"type":51,"coordinates":67},[68,69],5.08056,52.02917,{"lat":69,"lon":68},[72,76],{"name":73,"role":38,"phone":74,"phoneExt":40,"email":75},"Hjalmar C. van Santvoort, Prof. dr.","0883201942","h.van.santvoort@antoniusziekenhuis.nl",{"name":77,"role":38,"phone":78,"phoneExt":40,"email":41},"Hannah Pauw, drs.","0623559868",{"type":34,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"HC van Santvoort","dr. prof.","100527428",false,"NCT06147635","Prophylactic Tributyrin Supplementation in Acute Pancreatitis","Prophylactic Tributyrin Supplementation in Acute Pancreatitis; a Phase IIa (Proof of Concept) Double-blind Randomized Placebo-controlled Food Supplement Trial","PARROT","Inclusion Criteria:\n\n* First episode of acute pancreatitis (AP)\n* Able to read and\u002For understand the study procedures\n* Able to give informed consent (or their legal representatives)\n* \\\u003C24 hours after diagnosis of AP\n* \\\u003C72 hours after onset of symptoms of AP\n\nExclusion Criteria:\n\n* Pancreatitis due to endoscopic retrograde cholangiopancreatography (ERCP), malignancy or trauma\n* Post-operative pancreatitis\n* Intra-operative diagnosis\n* Immunocompromised patients (history or current immunosuppressive treatment such as chemotherapy, radiotherapy, longer use of immunosuppressive medication or recent high doses, immunocompromised illness' such as AIDS, leukemia, lymphoma)\n* Pregnancy and\u002For lactation\n* Age \\\u003C18 years old\n* History of recurrent or chronic (MANNHEIM criteria25) pancreatitis (see Appendix 15.1 for definition)","ALL","18 Years",{"count":92,"type":93},92,"ESTIMATED","INTERVENTIONAL",[96],"PHASE2","The goal of this clinical trial is to investigate the possible effects of tributyrin supplementation in patients with a first episode of acute pancreatitis. The main question it aims to answer is:\n\n• The effect of oral tributyrin supplementation on the plasma endotoxin level\n\nParticipants will be randomized between two groups: intervention and control group. They will receive:\n\n\\- three times daily 4grams of micro-encapsulated granules of tributyrin, and the control group three times daily 4 grams of micro-encapsulated sunflower oil (i.e. placebo), for a total of 14 days\n\nIn total 92 adult patients with a first episode of acute pancreatitis will be included.",[99],"Acute Pancreatitis","2024-06-17",{"date":102,"type":103},"2024-06-20","ACTUAL",{"date":105,"type":103},"2024-02-12",{"date":107,"type":93},"2027-01",{"name":5,"class":6},2]